West Pharmaceutical Services Inc at Bank of America Merrill Lynch Health Care Conference Transcript
We have their CFO and Quintin Lai from IR. So we'll go ahead and get started. Bernard, can you start out by summarizing your first quarter results and the factors that drove performance? That would be good.
Okay. So the first quarter was pretty strong which we were pleased to see. We saw growth across our market units which was positive. And we have organic growth of approximately 11% in the quarter and again led by biologics which was again very positive for us to see that market unit continue its rebound and get back to the growth rates that we would expect it to be achieving. And that also drives our high-value product growth rates which is very important from an overall profitability point of view. Generics, again, come in pretty strong. Our pharma division, excluding the Vial2Bag recall impact on revenue, again, was pretty much in line with where we expected it to be for the first quarter. And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
